The review concluded that iron supplementation safely improved haematologic and non-haematologic outcomes among primary school aged children in low or middle income settings, and was well-tolerated. The authors' conclusions may be affected by potential biases in the evidence, and some results were derived from a small subset of studies; the reliability of the conclusions is uncertain.
Study selection
Randomised controlled trials (RCTs) that evaluated daily (five or more days a week) iron supplementation compared to control in primary-school-aged children (five to 12 years) were eligible for inclusion. Studies that did not specifically recruit children within five to 12 years were included if: the mean or median age was between five and 12 years old; more than 75% of children were five to 12 years old; most of the studies recruitment age overlapped five to 12 years. Studies of only children with a known developmental disability or a condition that substantially altered iron metabolism, including severe anaemia, were excluded. The primary outcomes were cognitive performance, physical growth, safety (as defined in review), haemoglobin, iron indices, prevalence of anaemia and iron deficiency. Secondary outcomes were the effects of iron on other micronutrients and physical performance.
All studies except two were conducted in low or middle income settings. Iron supplementation (ferrous sulphate) dose varied between studies. Some studies included concurrent anthelmintic therapy, levamisole, folate, mebendazole, zinc, albendazole, and multi-vitamins. Control groups included anthelmintic therapy, placebo, no intervention, zinc, folate, or were just reported as "control".
Three reviewers selected studies for inclusion. Discrepancies were resolved through discussion.
Assessment of study quality
Study quality was assessed using the Cochrane Risk of Bias assessment tool. The authors did not state how many reviewers assessed quality.
Data extraction
Data were extracted to calculate mean differences between outcomes or mean changes from baseline for continuous data using the same scale, or standardised mean differences (SMD) if using a different scale. Risk Ratios were calculated for dichotomous data. Corresponding 95% confidence intervals were also calculated. Studies with a cointervention were included in the analysis providing this was applied identically in the control arm. Studies with separate intervention arms were analysed separately.
Two reviewers independently extracted data which was checked by a third reviewer. Discrepancies were resolved through discussion.
Methods of synthesis
Pooled standardised mean differences, mean differences and risk ratios with their 95% confidence intervals were calculated using a random-effects model when at least two studies provided data. Statistical heterogeneity was assessed
